Talazoparib (Talzenna™)


Indications for Prior Authorizations: 
  • Indicated in adult patients with deleterious or suspected deleterious germline BReast CAncer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.
Must meet the following criteria for coverage: 
  • Patient is of 18 years of age or older, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Patient has locally-advanced or metastatic breast cancer, AND
  • Patient has germline BRCA mutation-positive disease, AND
  • Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer
  • 1 mg taken orally once daily
  • 0.25 mg capsule is available for dose reduction

1 year


Last review date: December 4, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.